237 InnovaTV 301/Engot-Cx12/gog-3057: a Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin Versus Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer
International Journal of Gynecological Cancer（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined